PLAU and COVID-19: In consequence of high plasma levels of PAI-1, fibrinolysis mediated by tissue plasminogen activator (tPA) and urokinase plasminogen-activator (uPA) may be severely reduced51 and could lead to a fibrinolytic shutdown, which is frequently seen in COVID-19 patients52–55.